<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232696</url>
  </required_header>
  <id_info>
    <org_study_id>Neuspera Medical (NSM)-004</org_study_id>
    <secondary_id>SANS-UUI</secondary_id>
    <nct_id>NCT04232696</nct_id>
  </id_info>
  <brief_title>Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Overactive Bladder</brief_title>
  <official_title>Clinical Study of Neuspera's Implantable Sacral Nerve Stimulation (SNS) System in Patients With Symptoms of Overactive Bladder (OAB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuspera Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuspera Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, single-arm, seamless phase-pivotal study conducted in participants
      diagnosed with UUI who have failed or could not tolerate more conservative treatment. The
      trial will be conducted in two phases.

      Objective of Phase I: To assess the utilization of the system during the Sacral Nerve
      Stimulation (SNS) trial period and to help inform the length of hours of daily stimulation to
      be used in Phase II of the trial.

      Objective of Phase II: To assess the safety and efficacy of the Neuspera SNS System at
      6-months for the primary efficacy endpoint and at 12 months for secondary safety and efficacy
      endpoints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuspera's Implantable Sacral Nerve Stimulation (SNS) System is indicated to treat
      participants with UUI who have failed or could not tolerate more conservative treatments.

      The study will be conducted in two phases: Phase I of the study will be conducted at up to 6
      clinical study sites in the US and Europe. Phase II of the study will be conducted in up to
      20 clinical sites in the US and Europe, inclusive of the Phase I centers.

      Prospective, multi-center, single-arm, seamless phase-pivotal study. Objective of Phase I: To
      assess the utilization of the system during the Sacral Nerve Stimulation (SNS) trial period
      and to help inform the length of hours of daily stimulation to be used in Phase II of the
      trial.

      Objective of Phase II: To assess the safety and efficacy of the Neuspera SNS System at
      6-months for the primary efficacy endpoint and at 12 months for secondary safety and efficacy
      endpoints. All participants will receive the same length of device stimulation as determined
      in Phase I testing.

      Phase I will enroll 40 participants. Phase II will enroll up to 170 participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, seamless two-phased pivotal study design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase II Primary Efficacy Endpoint: Defined as the percentage of participants who experience a 50 percent or more change in Urinary Urgency Incontinence episodes.</measure>
    <time_frame>Six months</time_frame>
    <description>Change in Urinary Urgency Incontinence episodes at six months post-completion of the trial phase, relative to the number of Urinary Urgency Incontinence episodes at baseline prior to the trial phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II Primary Safety Endpoint: Defined as the incidence of device-related serious adverse events in the post-trial period follow-up.</measure>
    <time_frame>Six months</time_frame>
    <description>The number of serious adverse events related to the device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II Urinary Urgency Frequency Change</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Change in voids/day or a return to normal voiding (less than 8 voids/day) compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Change in Quality of Life: Measured from baseline as measured and assessed by the total and subset International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life score.</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Total score (25 min,160 max) with higher score indicating increase impact on quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Comprehensive Summary of all Adverse Events</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>The incidence of adverse events will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Device Parameter Information Collected</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Device amplitude will be collected in volts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Physician and Subject User Experience Questionnaire</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Physician and subject satisfaction will be obtained by answering questions on the use of the device using a five point scale:strongly agree, agree, neither agree nor disagree, disagree, strongly disagree. Answers towards strongly agree indicate a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Urinary Tract Symptoms Questionnaire: International Consultation on Incontinence Questionnaire Female &amp; Male Lower Urinary Tract Symptoms Modules</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Change in male/female lower urinary tract symptoms questionnaire. Male questionnaire score ranges from 0-52 and female questionnaire score ranges from 0-48. Higher number indicates worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Efficacy Endpoint: Defined as the percentage of participants who experience a 50 percent or more change in Urinary Urgency Incontinence.</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Urinary Urgency Incontinence episodes at 12 months post-completion of the trial phase, relative to the number of Urinary Urgency Incontinence episodes at baseline prior to the trial phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Safety Endpoint: Defined as the incidence of device-related serious adverse events in the post-trial period follow-up.</measure>
    <time_frame>12 months</time_frame>
    <description>The number of serious adverse events related to the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Urinary Output</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Total urinary output as measured by 72-hour bladder diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Change in Fecal Incontinence Episodes</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Change in fecal incontinence episodes compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Fecal Incontinence Measured by Wexner Scale</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Fecal incontinence as measured by the Wexner Scale compared to baseline. Wexner scale total points 0-20, higher the score the worse the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Patient Global Impression of Improvement</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Patient Global Impression of Improvement measured after implant during follow-up. Single question answered on a seven point scale: very much better, much better, a little better, no change, a little worse, much worse, very much worse. Selection of very much better is the best outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Urinary Urgency Incontinence</condition>
  <arm_group>
    <arm_group_label>Neuspera Implantable Sacral Nerve Stimulation System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of the simulator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuspera Implantable Sacral Nerve Stimulation System</intervention_name>
    <description>Stimulation of the Sacral Nerve.</description>
    <arm_group_label>Neuspera Implantable Sacral Nerve Stimulation System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has a Body Mass Index (BMI) between 18 and 35.

          2. Has a diagnosis of UUI for greater than or equal to 6 months prior to the screening
             baseline visit date.

          3. Has failed or was not a candidate for more conservative treatment (e.g. pelvic floor
             training, biofeedback, behavioral modification).

          4. Has failed or could not tolerate (stopped taking medication due to lack of efficacy or
             intolerable side effects) at least one (1) antimuscarinic or Î²3 adrenoceptor agonist
             medication.

          5. Has a diagnosis of UUI with at least 4 UUI episodes on a 72-hour diary, and minimum of
             one (1) UUI episode per 24-hour period.

        Exclusion Criteria:

          1. Has severe or uncontrolled diabetes mellitus, defined as being a diabetic with a
             hemoglobin A1c of greater than 8 percent or has diabetes mellitus with glucosuria.

          2. Has diabetic neuropathy.

          3. Has interstitial cystitis or bladder pain syndrome as defined by either American
             Urological Association (AUA) or European Association of Urology (EAU) guidelines,
             chronic pelvic pain or recurrent symptomatic urinary tract infections.

          4. Has neurogenic bladder dysfunction such as traumatic or atraumatic myelopathy,
             multiple sclerosis, Parkinsonism, or history of cerebrovascular accident.

          5. Has documented urinary retention within 6 months prior to the screening baseline visit
             date.

          6. Has clinically significant bladder outlet obstruction.

          7. Is a male subject with a mechanical obstruction such as benign prostatic hypertrophy,
             prostate surgery, urethral stricture or cancer.

          8. Has primary stress incontinence or mixed incontinence where the stress component
             predominates or has been treated surgically for stress urinary incontinence within 6
             months prior to the screening baseline visit date.

          9. Has received tibial nerve stimulation (TNS) in the past 3 months for the treatment of
             overactive bladder or unwilling to stay off TNS therapy for 12-month period following
             implant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark C Director of Clinical Research, BS</last_name>
    <phone>408-433-3839</phone>
    <email>mark.vollmer@neuspera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrina J SVP, Clinical Research, Regulatory Affairs, and Reimbursement, BA, MHA</last_name>
    <phone>408-433-3839</phone>
    <email>andrina.hougham@neuspera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Women's Health Advantage</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Brousseau</last_name>
      <phone>260-432-4400</phone>
      <phone_ext>6367</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Urology</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane L Kachel</last_name>
      <phone>651-999-7032</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adult &amp; Pediatric Urology P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Nelson</last_name>
      <phone>402-339-7892</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Wilson</last_name>
      <phone>315-478-4185</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Sparks</last_name>
      <phone>206-341-0896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Weber</last_name>
      <phone>+31(0)43-3876169</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://neuspera.com</url>
    <description>Neuspera Medical web page</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UUI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>At this time, there is no plan to share information.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

